Latest filing published 03 Jun 2024 for Celldex Therapeutics, Inc., €28k.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Sarah Cavanaugh: trading record in brief
Sarah Cavanaugh (senior executive) discloses dealings in Celldex Therapeutics, Inc. to SEC (Form 4). In total, 16 filings cover trades dated from 10 June 2020 to 30 May 2024.
Market trades split into 1 purchase (€4,462) and 7 sales (€2.4M). On balance, insiders were net sellers of €2.4M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 8 option exercises. 2024 to date brings no purchases and 1 sale.
Most recently, on 3 June 2024, the filings show an option exercise worth €84k in Celldex Therapeutics, Inc. The last insider purchase was made public on 11 June 2020, 2,342 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Sarah Cavanaugh
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 10,750 shares@ US$2.7812.5% of flowCommon StockSEC:0001415889-24-015138:0
- 31,312 shares@ US$2.7838.7% of flowCommon StockSEC:0001415889-22-008896:0
- 1,857 shares@ US$9.01658.9% of flowCommon StockSEC:0001179110-21-010820:0
- 5,018 shares@ US$9.016523.4% of flowCommon StockSEC:0001179110-21-009818:0
4 of 4 declarations